Should I buy RXO, Inc. (RXO) stock or is it too late?

RXO, Inc. · Industrials · price $29

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 63% of its targets hit on this sector (87 calls tested). It aims for $23 (-20 %), call made on August 8, 2026, maturing on August 8, 2027 (67 d ago).

The 2 reliable analysts $26.50-7.4 %

The 12 other firms $30+4.9 %

How to read it: the 2 reliable firms are not filtered by optimism — 1 aim above the price, 1 below, hence their $26.50 median. “The 12 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on RXO, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Susquehanna	67 %	+11.0 %	9	$19 -34%
Barclays	20 %	-8.4 %	5	$28 -2%
JP Morgan	40 %	-16.9 %	5	$30 +5%
Oppenheimer	33 %	-5.7 %	6	—

In short — Should you invest in RXO, Inc.? Is it too late, still worth it? Analysts are split (36% buy, median target $30, i.e. +5%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 14 ratings, only 5 buys, and the median price target ($30) is barely above the price (+5%, at $29). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on RXO, Susquehanna (67% hit rate, 9 scored calls), only targets $19 (call made on September 23, 2026, maturing on September 23, 2027) (-34%) in its most recent call, and $10 (call made on November 7, 2025, maturing on November 7, 2026) (-65%) in the one coming due soonest. The stock may already have run past its target.
The consensus is not unanimous: of 14 ratings, 9 are neutral.
Limited upside: the median target is only +5% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on RXO

Median target $30 (+5%) · 14 ratings · Hold consensus

Strong Buy00%

Buy536%

Hold964%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in RXO, Inc. now?

We won't decide for you. The facts: 36% of analysts rate it a buy, median target $30 (+5%), and Susquehanna (most reliable on RXO, 67%) targets $19. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in RXO, Inc.?

Not according to analysts: the median target ($30) is still +5% above the current price ($29) (most reliable on RXO: Susquehanna, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is RXO, Inc. still worth investing in?

It depends on the gap between the price ($29) and its estimated value: analysts target $30 on median (+5%), with 36% buys (most reliable on RXO: Susquehanna, 67%). Cross-check with their real reliability on RXO and the cautions above. Information, not advice.

What's the main risk in buying RXO?

Even the most reliable firm on RXO, Susquehanna (67% hit rate, 9 scored calls), only targets $19 (call made on September 23, 2026, maturing on September 23, 2027) (-34%) in its most recent call, and $10 (call made on November 7, 2025, maturing on November 7, 2026) (-65%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full RXO, Inc. profile (consensus, analyst reliability, price target, performance).